Publikationen
Veröffentlichungen des Instituts für Zellbiologie und Immunologie
Olayioye, MA, Barisic, S, Hausser, A. 2013. Multi-level control of actin dynamics by protein kinase D . Cellular Signalling (accepted for publication)
Kakarla, S, Chow, KKH, Mata, M, Shaffer, DR, Song, XT, Wu, MF, Liu, H, Wang, LL, Rowley, DR, Pfizenmaier, K, Gottschalk S. 2013. Anti-tumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol Ther (accepted for publication)
Ellwanger, K, Hausser, A. 2013. Physiological functions of protein kinase D in vivo. IUBMB Life 65(2): 98-107. PM: 23288632.
Kienzle, C, Eisler, SA, Villeneuve, J, Brummer, T, Olayioye, MA, Hausser, A. 2013. PKD controls mitotic Golgi complex fragmentation through a Raf-MEK1 pathway. Mol Biol Cell 24(3):222-33.PM:23242995.
Wahl, K, Siegemund, M, Lehner, F, Vondran, F, Nussler, A, Langer, F, Krech, T, Kontermann, R, Manns, MP, Schulze-Osthoff, K, Pfizenmaier, K, and Bantel, H. 2013. Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib. Hepatology 57(2):625-36. PM:22991197.
Kakarla, S, Chow, KKH, Mata, M, Shaffer, DR, Song, XT, Wu, MF, Liu, H, Wang, LL, Rowley, DR, Pfizenmaier, K, Gottschalk S. 2013. Anti-tumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol Ther (accepted for publication)
Ellwanger, K, Hausser, A. 2013. Physiological functions of protein kinase D in vivo. IUBMB Life 65(2): 98-107. PM: 23288632.
Kienzle, C, Eisler, SA, Villeneuve, J, Brummer, T, Olayioye, MA, Hausser, A. 2013. PKD controls mitotic Golgi complex fragmentation through a Raf-MEK1 pathway. Mol Biol Cell 24(3):222-33.PM:23242995.
Wahl, K, Siegemund, M, Lehner, F, Vondran, F, Nussler, A, Langer, F, Krech, T, Kontermann, R, Manns, MP, Schulze-Osthoff, K, Pfizenmaier, K, and Bantel, H. 2013. Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib. Hepatology 57(2):625-36. PM:22991197.
Muller, D. 2012. Targeted cancer immunotherapy: Mimicking physiological trans-presentation of IL-15. Oncoimmunology. 1: 1213-1214. PM:23170284.
Seifert, O, Plappert, A, Heidel, N, Fellermeier, S, Messerschmidt, SK, Richter, F, and Kontermann, RE. 2012. The IgM CH2 domain as covalently linked homodimerization module for the generation of fusion proteins with dual specificity. Protein Eng Des Sel. 25: 603-612. PM:22988132.
Lopez-Ramirez, MA, Fischer, R, Torres-Badillo, CC, Davies, HA, Logan, K, Pfizenmaier, K, Male, DK, Sharrack, B, and Romero, IA. 2012. Role of Caspases in Cytokine-Induced Barrier Breakdown in Human Brain Endothelial Cells. J.Immunol. 189: 3130-3139. PM:22896632.
Huck, B, Kemkemer, R, Franz-Wachtel, M, Macek, B, Hausser, A, and Olayioye, MA. 2012. GIT1 phosphorylation on serine 46 by PKD3 regulates paxillin trafficking and cellular protrusive activity. J.Biol.Chem. 2012 Aug 13 [Epub ahead of print] PM:22893698.
Neumann S, Bidon T, Branschädel M, Krippner-Heidenreich A, Scheurich P, Doszczak M. 2012. The Transmembrane Domains of TNF-Related Apoptosis-Inducing Ligand (TRAIL) Receptors 1 and 2 Co-Regulate Apoptotic Signaling Capacity. PLoS One. 2012;7(8):e42526. PM:22916132.
Winkel C, Neumann S, Surulescu C, Scheurich P. 2012. A minimal mathematical model for the initial molecular interactions of death receptor signalling. Math Biosci Eng. 9(3):663-83. PM:22881031.
Mack, K, Ruger, R, Fellermaier, S, Seifert, O, and Kontermann, RE. 2012. Dual Targeting of Tumor Cells with Bispecific Single-Chain Fv-Immunoliposomes. Antibodies. 1: 199-214. doi:10.3390/antib1020199.
Holeiter, G, Bischoff, A, Braun, AC, Huck, B, Erlmann, P, Schmid, S, Herr, R, Brummer, T, and Olayioye, MA. 2012. The RhoGAP protein Deleted in Liver Cancer 3 (DLC3) is essential for adherens junctions integrity. Oncogenesis. e13: doi:10.1038/oncsis.2012.13..
Schildknecht, S, Kirner, S, Henn, A, Gasparic, K, Pape, R, Efremova, L, Maier, O, Fischer, R, and Leist, M. 2012. Characterization of mouse cell line IMA 2.1 as a potential model system to study astrocyte functions. ALTEX. 29: 261-274. PM:22847254.
Witt, J, Konrath, F, Sawodny, O, Ederer, M, Kulms, D, and Sauter, T. 2012. Analysing the Role of UVB-Induced Translational Inhibition and PP2Ac Deactivation in NF-kappaB Signalling Using a Minimal Mathematical Model. PLOS one. 7: e40274. PM:22815735.
Hasenauer, J, Heinrich, J, Doszczak, M, Scheurich, P, Weiskopf, D, Allgower, F. 2012. A visual analytics approach for models of heterogeneous cell populations. EURASIP J Bioinform Syst Biol. May 31;2012(1):4. PM:22651376.
Richter, C, Messerschmidt, S, Holeiter, G, Tepperink, J, Osswald, S, Zappe, A, Branschädel, M, Boschert, V, Mann, DA, Scheurich, P, Krippner-Heidenreich, A. 2012. The Tumor Necrosis Factor Receptor Stalk Regions Define Responsiveness to Soluble versus Membrane-Bound Ligand. Mol Cell Biol. 32(13):2515-29. PM:22547679.
Eisler, SA, Fuchs, YF, Pfizenmaier, K, and Hausser, A. 2012. G-PKDrep-live, a genetically encoded FRET reporter to measure PKD activity at the trans-Golgi-network. Biotechnol.J. 7: 148-154. PM:21898831.
Unverdorben, F, Farber-Schwarz, A, Richter, F, Hutt, M, and Kontermann, RE. 2012. Half-life extension of a single-chain diabody by fusion to domain B of staphylococcal protein A. Protein Eng Des Sel. 25: 81-88. PM:22238430.
Hutt, M, Farber-Schwarz, A, Unverdorben, F, Richter, F, and Kontermann, RE. 2012. Plasma Half-life Extension of Small Recombinant Antibodies by Fusion to Immunoglobulin-binding Domains. J.Biol.Chem. 287: 4462-4469. PM:22147690.
Daub, M, Waldherr, S, Allgower, F, Scheurich, P, and Schneider, G. 2012. Death wins against life in a spatially extended model of the caspase-3/8 feedback loop. Biosystems. 108: 45-51. PM:22289626.
Heering, J, Weis, N, Holeiter, M, Neugart, F, Staebler, A, Fehm, TN, Bischoff, A, Schiller, J, Duss, S, Schmid, S, Korte, T, Herrmann, A, and Olayioye, MA. 2012. Loss of the ceramide transfer protein augments epidermal growth factor receptor signaling in breast cancer. Cancer Res. 72: 2855-2866. PM:22472120.
Siegemund, M, Pollak, N, Seifert, O, Wahl, K, Hanak, K, Vogel, A, Nussler, AK, Gottsch, D, Munkel, S, Bantel, H, Kontermann, RE, and Pfizenmaier, K. 2012. Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity. Cell Death Dis. 3: e295 PM:22495350.
Kontermann, R. 2012. Dual targeting strategies with bispecific antibodies. MAbs. 4: PM:22453100.
Kontermann, RE. 2012. Antibody-cytokine fusion proteins. Arch.Biochem.Biophys. 526: 194-205. PM:22445675.
Kermer, V, Baum, V, Hornig, N, Kontermann, RE, and Muller, D. 2012. An antibody fusion protein for cancer immunotherapy mimicking IL-15 trans-presentation at the tumor site. Mol.Cancer Ther. 11: 1279-1288 PM:22491823.
Hornig, N, Kermer, V, Frey, K, Diebolder, P, Kontermann, RE, and Muller, D. 2012. Combination of a bispecific antibody and costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy. J.Immunother. 35: 418-429. PM:22576347.
Moosmann, A, Gerlach, E, Lindner, R, and Bottinger, H. 2012. Purification of a PEGylated single chain Fv. J.Chromatogr.A. 1236: 90-96. PM:22444429.
Kempkes, C, Rattenholl, A, Buddenkotte, J, Strozyk, E, Eberle, J, Hausser, A, Cevikbas, F, Schneider, SW, and Steinhoff, M. 2012. Proteinase-activated receptors 1 and 2 regulate invasive behavior of human melanoma cells via activation of protein kinase D1. J.Invest Dermatol. 132: 375-384. PM:21993564.
Franz-Wachtel, M, Eisler, SA, Krug, K, Wahl, S, Carpy, A, Nordheim, A, Pfizenmaier, K, Hausser, A, and Macek, B. 2012. Global Detection of Protein Kinase D-dependent Phosphorylation Events in Nocodazole-treated Human Cells. Mol.Cell Proteomics. 11: 160-170. PM:22496350.
Olayioye, MA and Hausser, A. 2012. Integration of non-vesicular and vesicular transport processes at the Golgi complex by the PKD-CERT network. Biochim.Biophys.Acta. 1821: 1096-1103 PM:22226883 PM:22226883.
Fischer, R, Maier, O, Naumer, M, Krippner-Heidenreich, A, Scheurich, P, and Pfizenmaier, K. 2011. Ligand-induced internalization of TNF receptor 2 mediated by a di-leucin motif is dispensable for activation of the NFkappaB pathway. Cell Signal. 23: 161-170. PM:20807567.
Gerspach, J, Schneider, B, Muller, N, Otz, T, Wajant, H, and Pfizenmaier, K. 2011. Genetic engineering of death ligands for improvement of therapeutic activity. Adv.Exp.Med.Biol. 691: 507-519. PM:21153356.
Pfizenmaier, K and Szymkowski, DE. 2011. Workshop Summary: Introduction to Rational Design of New Means for Therapeutic Modulation of Function of the TNF Family. Adv.Exp.Med.Biol. 691: 487-491. PM:21153353.
Chertoff, M, Di Paolo, N, Schoeneberg, A, Depino, A, Ferrari, C, Wurst, W, Pfizenmaier, K, Eisel, U, and Pitossi, F. 2011. Neuroprotective and neurodegenerative effects of the chronic expression of tumor necrosis factor alpha in the nigrostriatal dopaminergic circuit of adult mice. Exp.Neurol. 227: 237-251. PM:21093436.
Niessner, H, Beck, D, Sinnberg, T, Lasithiotakis, K, Maczey, E, Gogel, J, Venturelli, S, Berger, A, Mauthe, M, Toulany, M, Flaherty, K, Schaller, M, Schadendorf, D, Proikas-Cezanne, T, Schittek, B, Garbe, C, Kulms, D, and Meier, F. 2011. The Farnesyl Transferase Inhibitor Lonafarnib Inhibits mTOR Signaling and Enforces Sorafenib-Induced Apoptosis in Melanoma Cells. J.Invest Dermatol. 131: 468-479. PM:20944654.
Ziegler, S, Eiseler, T, Scholz, RP, Beck, A, Link, G, and Hausser, A. 2011. A novel protein kinase D phosphorylation site in the tumor suppressor Rab interactor 1 is critical for coordination of cell migration. Mol.Biol.Cell. 22: 570-580. PM:21209314.
Hornle, M, Peters, N, Thayaparasingham, B, Vorsmann, H, Kashkar, H, and Kulms, D. 2011. Caspase-3 cleaves XIAP in a positive feedback loop to sensitize melanoma cells to TRAIL-induced apoptosis. Oncogene. 30: 575-587. PM:20856198.
Scholz, RP, Gustafsson, JO, Hoffmann, P, Jaiswal, M, Ahmadian, MR, Eisler, SA, Erlmann, P, Schmid, S, Hausser, A, and Olayioye, MA. 2011. The tumor suppressor protein DLC1 is regulated by PKD-mediated GAP domain phosphorylation. Exp.Cell Res. 317: 496-503. PM:21087603.
Wajant, H, Gerspach, J, and Pfizenmaier, K. 2011. Engineering death receptor ligands for cancer therapy. Cancer Lett. [Epub ahead of print]: PM:21236560.
Hasenauer, J, Waldherr, S, Doszczak, M, Radde, N, Scheurich, P, and Allgower, F. 2011. Identification of models of heterogeneous cell populations from population snapshot data. BMC Bioinformatics. 12: 125 PM:21527025.
Wajant, H and Scheurich, P. 2011. TNFR1-induced activation of the classical NF-kappaB pathway. FEBS J. 278: 862-876. PM:21232017.
Barisic, S, Nagel, AC, Franz-Wachtel, M, Macek, B, Preiss, A, Link, G, Maier, D, and Hausser, A. 2011. Phosphorylation of Ser 402 impedes phosphatase activity of slingshot 1. EMBO Rep. 12: 527-533. PM:21525957.
Moosmann, A, Blath, J, Lindner, R, Muller, E, and Bottinger, H. 2011. Aldehyde PEGylation Kinetics: A Standard Protein versus a Pharmaceutically Relevant Single Chain Variable Fragment. Bioconjug.Chem. 22: 1545-1558. PM:21780828.
Gerspach, J, Pfizenmaier, K, and Wajant, H. 2011. Therapeutic Targeting of CD95 and the TRAIL Death Receptors. Recent Pat Anticancer Drug Discov. 6: 294-310. PM:21762072.
Gehrmann, M, Doss, BT, Wagner, M, Zettlitz, KA, Kontermann, RE, Foulds, G, Pockley, AG, and Multhoff, G. 2011. A novel expression and purification system for the production of enzymatic and biologically active human granzyme B. J.Immunol.Methods. 371: 8-17. PM:21723287.
Witt, J, Barisic, S, Sawodny, O, Ederer, M, Kulms, D, and Sauter, T. 2011. Modeling time delay in the NFkappaB signaling pathway following low dose IL-1 stimulation. EURASIP J.Bioinform.Syst.Biol. 2011: 3 PM:21910922.
Dengler, MA, Staiger, AM, Gutekunst, M, Hofmann, U, Doszczak, M, Scheurich, P, Schwab, M, Aulitzky, WE, and van der, KH. 2011. Oncogenic Stress Induced by Acute Hyper-Activation of Bcr-Abl Leads to Cell Death upon Induction of Excessive Aerobic Glycolysis. PLOS one. 6: e25139 PM:21949869.
Fischer, R, Maier, O, Siegemund, M, Wajant, H, Scheurich, P, and Pfizenmaier, K. 2011. A TNF receptor 2 selective agonist rescues human neurons from oxidative stress-induced cell death. PLOS one. 6: e27621 PM:22110694.
Ellwanger, K, Kienzle, C, Lutz, S, Jin, ZG, Wiekowski, MT, Pfizenmaier, K, and Hausser, A. 2011. Protein kinase D controls voluntary-running-induced skeletal muscle remodelling. Biochem.J. 440: 327-4. PM:21848513.
Ranzinger, J, Rustom, A, Abel, M, Leyh, J, Kihm, L, Witkowski, M, Scheurich, P, Zeier, M, and Schwenger, V. 2011. Nanotube action between human mesothelial cells reveals novel aspects of inflammatory responses. PLOS one. 6: e29537 PM:22216308.
Kontermann, RE. 2011. Strategies for extended serum half-life of protein therapeutics. Curr.Opin.Biotechnol. 22: 868-876. PM:21862310.
Schliemann, M, Bullinger, E, Borchers, S, Allgower, F, Findeisen, R, and Scheurich, P. 2011. Heterogeneity reduces sensitivity of cell death for TNF-stimuli. BMC Syst.Biol. 5: 204 PM:22204418.
Krenz, B, Neugart, F, Kleinow, T, and Jeske, H. 2011. Self-interaction of Abutilon mosaic virus replication initiator protein (Rep) in plant cell nuclei. Virus Res. 161: 194-197. PM:21840354.
Gerspach, J, Schneider, B, Muller, N, Otz, T, Wajant, H, and Pfizenmaier, K. 2011. Genetic engineering of death ligands for improvement of therapeutic activity. Adv.Exp.Med.Biol. 691: 507-519. PM:21153356.
Pfizenmaier, K and Szymkowski, DE. 2011. Workshop Summary: Introduction to Rational Design of New Means for Therapeutic Modulation of Function of the TNF Family. Adv.Exp.Med.Biol. 691: 487-491. PM:21153353.
Chertoff, M, Di Paolo, N, Schoeneberg, A, Depino, A, Ferrari, C, Wurst, W, Pfizenmaier, K, Eisel, U, and Pitossi, F. 2011. Neuroprotective and neurodegenerative effects of the chronic expression of tumor necrosis factor alpha in the nigrostriatal dopaminergic circuit of adult mice. Exp.Neurol. 227: 237-251. PM:21093436.
Niessner, H, Beck, D, Sinnberg, T, Lasithiotakis, K, Maczey, E, Gogel, J, Venturelli, S, Berger, A, Mauthe, M, Toulany, M, Flaherty, K, Schaller, M, Schadendorf, D, Proikas-Cezanne, T, Schittek, B, Garbe, C, Kulms, D, and Meier, F. 2011. The Farnesyl Transferase Inhibitor Lonafarnib Inhibits mTOR Signaling and Enforces Sorafenib-Induced Apoptosis in Melanoma Cells. J.Invest Dermatol. 131: 468-479. PM:20944654.
Ziegler, S, Eiseler, T, Scholz, RP, Beck, A, Link, G, and Hausser, A. 2011. A novel protein kinase D phosphorylation site in the tumor suppressor Rab interactor 1 is critical for coordination of cell migration. Mol.Biol.Cell. 22: 570-580. PM:21209314.
Hornle, M, Peters, N, Thayaparasingham, B, Vorsmann, H, Kashkar, H, and Kulms, D. 2011. Caspase-3 cleaves XIAP in a positive feedback loop to sensitize melanoma cells to TRAIL-induced apoptosis. Oncogene. 30: 575-587. PM:20856198.
Scholz, RP, Gustafsson, JO, Hoffmann, P, Jaiswal, M, Ahmadian, MR, Eisler, SA, Erlmann, P, Schmid, S, Hausser, A, and Olayioye, MA. 2011. The tumor suppressor protein DLC1 is regulated by PKD-mediated GAP domain phosphorylation. Exp.Cell Res. 317: 496-503. PM:21087603.
Wajant, H, Gerspach, J, and Pfizenmaier, K. 2011. Engineering death receptor ligands for cancer therapy. Cancer Lett. [Epub ahead of print]: PM:21236560.
Hasenauer, J, Waldherr, S, Doszczak, M, Radde, N, Scheurich, P, and Allgower, F. 2011. Identification of models of heterogeneous cell populations from population snapshot data. BMC Bioinformatics. 12: 125 PM:21527025.
Wajant, H and Scheurich, P. 2011. TNFR1-induced activation of the classical NF-kappaB pathway. FEBS J. 278: 862-876. PM:21232017.
Barisic, S, Nagel, AC, Franz-Wachtel, M, Macek, B, Preiss, A, Link, G, Maier, D, and Hausser, A. 2011. Phosphorylation of Ser 402 impedes phosphatase activity of slingshot 1. EMBO Rep. 12: 527-533. PM:21525957.
Moosmann, A, Blath, J, Lindner, R, Muller, E, and Bottinger, H. 2011. Aldehyde PEGylation Kinetics: A Standard Protein versus a Pharmaceutically Relevant Single Chain Variable Fragment. Bioconjug.Chem. 22: 1545-1558. PM:21780828.
Gerspach, J, Pfizenmaier, K, and Wajant, H. 2011. Therapeutic Targeting of CD95 and the TRAIL Death Receptors. Recent Pat Anticancer Drug Discov. 6: 294-310. PM:21762072.
Gehrmann, M, Doss, BT, Wagner, M, Zettlitz, KA, Kontermann, RE, Foulds, G, Pockley, AG, and Multhoff, G. 2011. A novel expression and purification system for the production of enzymatic and biologically active human granzyme B. J.Immunol.Methods. 371: 8-17. PM:21723287.
Witt, J, Barisic, S, Sawodny, O, Ederer, M, Kulms, D, and Sauter, T. 2011. Modeling time delay in the NFkappaB signaling pathway following low dose IL-1 stimulation. EURASIP J.Bioinform.Syst.Biol. 2011: 3 PM:21910922.
Dengler, MA, Staiger, AM, Gutekunst, M, Hofmann, U, Doszczak, M, Scheurich, P, Schwab, M, Aulitzky, WE, and van der, KH. 2011. Oncogenic Stress Induced by Acute Hyper-Activation of Bcr-Abl Leads to Cell Death upon Induction of Excessive Aerobic Glycolysis. PLOS one. 6: e25139 PM:21949869.
Fischer, R, Maier, O, Siegemund, M, Wajant, H, Scheurich, P, and Pfizenmaier, K. 2011. A TNF receptor 2 selective agonist rescues human neurons from oxidative stress-induced cell death. PLOS one. 6: e27621 PM:22110694.
Ellwanger, K, Kienzle, C, Lutz, S, Jin, ZG, Wiekowski, MT, Pfizenmaier, K, and Hausser, A. 2011. Protein kinase D controls voluntary-running-induced skeletal muscle remodelling. Biochem.J. 440: 327-4. PM:21848513.
Ranzinger, J, Rustom, A, Abel, M, Leyh, J, Kihm, L, Witkowski, M, Scheurich, P, Zeier, M, and Schwenger, V. 2011. Nanotube action between human mesothelial cells reveals novel aspects of inflammatory responses. PLOS one. 6: e29537 PM:22216308.
Kontermann, RE. 2011. Strategies for extended serum half-life of protein therapeutics. Curr.Opin.Biotechnol. 22: 868-876. PM:21862310.
Schliemann, M, Bullinger, E, Borchers, S, Allgower, F, Findeisen, R, and Scheurich, P. 2011. Heterogeneity reduces sensitivity of cell death for TNF-stimuli. BMC Syst.Biol. 5: 204 PM:22204418.
Krenz, B, Neugart, F, Kleinow, T, and Jeske, H. 2011. Self-interaction of Abutilon mosaic virus replication initiator protein (Rep) in plant cell nuclei. Virus Res. 161: 194-197. PM:21840354.
Eiseler, T, Hausser, A, De Kimpe, L, Van Lint, J, and Pfizenmaier, K. 2010. Protein kinase D controls actin polymerization and cell motility through phosphorylation of cortactin. J.Biol.Chem. 285: 18672-18683. PM:20363754.
Joffroy, CM, Buck, MB, Stope, MB, Popp, SL, Pfizenmaier, K, and Knabbe, C. 2010. Antiestrogens induce transforming growth factor beta-mediated immunosuppression in breast cancer. Cancer Res. 70: 1314-1322. PM:20145137.
Becker, E, Florin, L, Pfizenmaier, K, and Kaufmann, H. 2010. Evaluation of a combinatorial cell engineering approach to overcome apoptotic effects in XBP-1(s) expressing cells. J.Biotechnol. 146: 198-206. PM:19958799.
Boschert, V, Krippner-Heidenreich, A, Branschadel, M, Tepperink, J, Aird, A, and Scheurich, P. 2010. Single chain TNF derivatives with individually mutated receptor binding sites reveal differential stoichiometry of ligand receptor complex formation for TNFR1 and TNFR2. Cell Signal. 22: 1088-1096. PM:20206684.
Gerken, M, Krippner-Heidenreich, A, Steinert, S, Willi, S, Neugart, F, Zappe, A, Wrachtrup, J, Tietz, C, and Scheurich, P. 2010. Fluorescence correlation spectroscopy reveals topological segregation of the two tumor necrosis factor membrane receptors. Biochim.Biophys.Acta. 1798: 1081-1089. PM:20188063.
Branschadel, M, Aird, A, Zappe, A, Tietz, C, Krippner-Heidenreich, A, and Scheurich, P. 2010. Dual function of cysteine rich domain (CRD) 1 of TNF receptor type 1: conformational stabilization of CRD2 and control of receptor responsiveness. Cell Signal. 22: 404-414. PM:19879354.
Kontermann, RE. 2010. Alternative antibody formats. Curr.Opin.Mol.Ther. 12: 176-183. PM:20373261.
Rothdiener, M, Beuttler, J, Messerschmidt, SK, and Kontermann, RE. 2010. Antibody targeting of nanoparticles to tumor-specific receptors: immunoliposomes. Methods Mol.Biol. 624: 295-308. PM:20217604.
Muller, D and Kontermann, RE. 2010. Bispecific antibodies for cancer immunotherapy: Current perspectives. BioDrugs. 24: 89-98. PM:20199124.
Rothdiener, M, Muller, D, Castro, PG, Scholz, A, Schwemmlein, M, Fey, G, Heidenreich, O, and Kontermann, RE. 2010. Targeted delivery of SiRNA to CD33-positive tumor cells with liposomal carrier systems. J.Control Release. 144: 251-258. PM:20184933.
Baum, P, Fundel-Clemens, K, Kreuz, S, Kontermann, RE, Weith, A, Mennerich, D, and Rippmann, JF. 2010. Off-target analysis of control siRNA molecules reveals important differences in the cytokine profile and inflammation response of human fibroblasts. Oligonucleotides. 20: 17-26. PM:20038253.
Murphy, NC, Biankin, AV, Millar, EK, McNeil, CM, O'Toole, SA, Segara, D, Crea, P, Olayioye, MA, Lee, CS, Fox, SB, Morey, AL, Christie, M, Musgrove, EA, Daly, RJ, Lindeman, GJ, Henshall, SM, Visvader, JE, and Sutherland, RL. 2010. Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status. Int.J.Cancer. 126: 1445-1453. PM:19676041.
Moosmann, A, Christel, J, Boettinger, H, and Mueller, E. 2010. Analytical and preparative separation of PEGylated lysozyme for the characterization of chromatography media. J.Chromatogr.A. 1217: 209-215. PM:19963219.
Hasenauer, J, Waldherr, S, Radde, N, Doszczak, M, Scheurich, P, and Allgower, F. 2010. A maximum likelihood estimator for parameter distributions in heterogenous cell populations. Procedia Computer Science. 1: 1649-1657.
Hasenauer, J, Waldherr, S, Doszczak, M, Scheurich, P, and Allgower, F. 2010. Density-based modeling and identification of biochemical networks in cell populations. Proc.of 9th International Symposium on Dynamics and Control of Process Systems (DYCOPS). Leuven, Belgium: 306-311.
Waldherr, S, Hasenauer, J, Doszczak, M, Scheurich, P, and Allgower, F. 2010. Global Uncertainty Analysis for a Model of TNF-induced NF-kB Signalling. Advances in the Theory of Control, Signals and Systems with Physical Modeling, Lecture Notes in Control and Information Sciences, Springer Berlin/Heidelberg. 407: 365-377.
Mueller, E, Josic, D, Schröder, T, and Moosmann, A. 2010. Solubility and binding properties of PEGylated lysozyme derivatives with increasing molecular weight on hydrophobic-interaction chromatographic resins. J.Chromatogr.A. 1217: 4696-4703. PM:19963219.
Zettlitz, KA, Lorenz, V, Landauer, K, Munkel, S, Herrmann, A, Scheurich, P, Pfizenmaier, K, and Kontermann, R. 2010. ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody. MAbs. 2: 639-647. PM:20935477.
Anliker, B, Abel, T, Kneissl, S, Hlavaty, J, Caputi, A, Brynza, J, Schneider, IC, Munch, RC, Petznek, H, Kontermann, RE, Koehl, U, Johnston, IC, Keinanen, K, Muller, UC, Hohenadl, C, Monyer, H, Cichutek, K, and Buchholz, CJ. 2010. Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors. Nat.Methods. 7: 929-935. PM:20935652.
Hopp, J, Hornig, N, Zettlitz, KA, Schwarz, A, Fuss, N, Muller, D, and Kontermann, RE. 2010. The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein. Protein Eng Des Sel. 23: 827-834. PM:20817756.
Zettlitz, KA, Seitter, J, Muller, D, and Kontermann, RE. 2010. Humanization of a mouse monoclonal antibody directed against a cell surface-exposed epitope of membrane-associated heat shock protein 70 (Hsp70). Mol.Biotechnol. 46: 265-278. PM:20556545.
Muller, N, Schneider, B, Pfizenmaier, K, and Wajant, H. 2010. Superior serum half life of albumin tagged TNF ligands. Biochem.Biophys.Res.Commun. 396: 793-799. PM:20447380. Barisic, S, Schmidt, C, Walczak, H, and Kulms, D. 2010. Tyrosine phosphatase inhibition triggers sustained canonical serine-dependent NFkappaB activation via Src-dependent blockade of PP2A. Biochem.Pharmacol. 80: 439-447. PM:20450893.
Brandt, S, Ellwanger, K, Beuter-Gunia, C, Schuster, M, Hausser, A, Schmitz, I, and Beer-Hammer, S. 2010. SLy2 targets the nuclear SAP30/HDAC1 complex. Int.J.Biochem.Cell Biol. 42: 1472-1481. PM:20478393.
Baum, P, Schmid, R, Ittrich, C, Rust, W, Fundel-Clemens, K, Siewert, S, Baur, M, Mara, L, Gruenbaum, L, Heckel, A, Eils, R, Kontermann, RE, Roth, GJ, Gantner, F, Schnapp, A, Park, JE, Weith, A, Quast, K, and Mennerich, D. 2010. Phenocopy--a strategy to qualify chemical compounds during hit-to-lead and/or lead optimization. PLOS one. 5: e14272 PM:21170314.
Schneider, B, Munkel, S, Krippner-Heidenreich, A, Grunwald, I, Wels, WS, Wajant, H, Pfizenmaier, K, and Gerspach, J. 2010. Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins. Cell Death Dis. 1: e68 PM:21364672.
Smolders, I, Smets, I, Maier, O, vandeVen, M, Steels, P, and Ameloot, M. 2010. Simvastatin interferes with process outgrowth and branching of oligodendrocytes. J.Neurosci.Res. 88: 3361-3375. PM:20857509.
Joffroy, CM, Buck, MB, Stope, MB, Popp, SL, Pfizenmaier, K, and Knabbe, C. 2010. Antiestrogens induce transforming growth factor beta-mediated immunosuppression in breast cancer. Cancer Res. 70: 1314-1322. PM:20145137.
Becker, E, Florin, L, Pfizenmaier, K, and Kaufmann, H. 2010. Evaluation of a combinatorial cell engineering approach to overcome apoptotic effects in XBP-1(s) expressing cells. J.Biotechnol. 146: 198-206. PM:19958799.
Boschert, V, Krippner-Heidenreich, A, Branschadel, M, Tepperink, J, Aird, A, and Scheurich, P. 2010. Single chain TNF derivatives with individually mutated receptor binding sites reveal differential stoichiometry of ligand receptor complex formation for TNFR1 and TNFR2. Cell Signal. 22: 1088-1096. PM:20206684.
Gerken, M, Krippner-Heidenreich, A, Steinert, S, Willi, S, Neugart, F, Zappe, A, Wrachtrup, J, Tietz, C, and Scheurich, P. 2010. Fluorescence correlation spectroscopy reveals topological segregation of the two tumor necrosis factor membrane receptors. Biochim.Biophys.Acta. 1798: 1081-1089. PM:20188063.
Branschadel, M, Aird, A, Zappe, A, Tietz, C, Krippner-Heidenreich, A, and Scheurich, P. 2010. Dual function of cysteine rich domain (CRD) 1 of TNF receptor type 1: conformational stabilization of CRD2 and control of receptor responsiveness. Cell Signal. 22: 404-414. PM:19879354.
Kontermann, RE. 2010. Alternative antibody formats. Curr.Opin.Mol.Ther. 12: 176-183. PM:20373261.
Rothdiener, M, Beuttler, J, Messerschmidt, SK, and Kontermann, RE. 2010. Antibody targeting of nanoparticles to tumor-specific receptors: immunoliposomes. Methods Mol.Biol. 624: 295-308. PM:20217604.
Muller, D and Kontermann, RE. 2010. Bispecific antibodies for cancer immunotherapy: Current perspectives. BioDrugs. 24: 89-98. PM:20199124.
Rothdiener, M, Muller, D, Castro, PG, Scholz, A, Schwemmlein, M, Fey, G, Heidenreich, O, and Kontermann, RE. 2010. Targeted delivery of SiRNA to CD33-positive tumor cells with liposomal carrier systems. J.Control Release. 144: 251-258. PM:20184933.
Baum, P, Fundel-Clemens, K, Kreuz, S, Kontermann, RE, Weith, A, Mennerich, D, and Rippmann, JF. 2010. Off-target analysis of control siRNA molecules reveals important differences in the cytokine profile and inflammation response of human fibroblasts. Oligonucleotides. 20: 17-26. PM:20038253.
Murphy, NC, Biankin, AV, Millar, EK, McNeil, CM, O'Toole, SA, Segara, D, Crea, P, Olayioye, MA, Lee, CS, Fox, SB, Morey, AL, Christie, M, Musgrove, EA, Daly, RJ, Lindeman, GJ, Henshall, SM, Visvader, JE, and Sutherland, RL. 2010. Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status. Int.J.Cancer. 126: 1445-1453. PM:19676041.
Moosmann, A, Christel, J, Boettinger, H, and Mueller, E. 2010. Analytical and preparative separation of PEGylated lysozyme for the characterization of chromatography media. J.Chromatogr.A. 1217: 209-215. PM:19963219.
Hasenauer, J, Waldherr, S, Radde, N, Doszczak, M, Scheurich, P, and Allgower, F. 2010. A maximum likelihood estimator for parameter distributions in heterogenous cell populations. Procedia Computer Science. 1: 1649-1657.
Hasenauer, J, Waldherr, S, Doszczak, M, Scheurich, P, and Allgower, F. 2010. Density-based modeling and identification of biochemical networks in cell populations. Proc.of 9th International Symposium on Dynamics and Control of Process Systems (DYCOPS). Leuven, Belgium: 306-311.
Waldherr, S, Hasenauer, J, Doszczak, M, Scheurich, P, and Allgower, F. 2010. Global Uncertainty Analysis for a Model of TNF-induced NF-kB Signalling. Advances in the Theory of Control, Signals and Systems with Physical Modeling, Lecture Notes in Control and Information Sciences, Springer Berlin/Heidelberg. 407: 365-377.
Mueller, E, Josic, D, Schröder, T, and Moosmann, A. 2010. Solubility and binding properties of PEGylated lysozyme derivatives with increasing molecular weight on hydrophobic-interaction chromatographic resins. J.Chromatogr.A. 1217: 4696-4703. PM:19963219.
Zettlitz, KA, Lorenz, V, Landauer, K, Munkel, S, Herrmann, A, Scheurich, P, Pfizenmaier, K, and Kontermann, R. 2010. ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody. MAbs. 2: 639-647. PM:20935477.
Anliker, B, Abel, T, Kneissl, S, Hlavaty, J, Caputi, A, Brynza, J, Schneider, IC, Munch, RC, Petznek, H, Kontermann, RE, Koehl, U, Johnston, IC, Keinanen, K, Muller, UC, Hohenadl, C, Monyer, H, Cichutek, K, and Buchholz, CJ. 2010. Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors. Nat.Methods. 7: 929-935. PM:20935652.
Hopp, J, Hornig, N, Zettlitz, KA, Schwarz, A, Fuss, N, Muller, D, and Kontermann, RE. 2010. The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein. Protein Eng Des Sel. 23: 827-834. PM:20817756.
Zettlitz, KA, Seitter, J, Muller, D, and Kontermann, RE. 2010. Humanization of a mouse monoclonal antibody directed against a cell surface-exposed epitope of membrane-associated heat shock protein 70 (Hsp70). Mol.Biotechnol. 46: 265-278. PM:20556545.
Muller, N, Schneider, B, Pfizenmaier, K, and Wajant, H. 2010. Superior serum half life of albumin tagged TNF ligands. Biochem.Biophys.Res.Commun. 396: 793-799. PM:20447380. Barisic, S, Schmidt, C, Walczak, H, and Kulms, D. 2010. Tyrosine phosphatase inhibition triggers sustained canonical serine-dependent NFkappaB activation via Src-dependent blockade of PP2A. Biochem.Pharmacol. 80: 439-447. PM:20450893.
Brandt, S, Ellwanger, K, Beuter-Gunia, C, Schuster, M, Hausser, A, Schmitz, I, and Beer-Hammer, S. 2010. SLy2 targets the nuclear SAP30/HDAC1 complex. Int.J.Biochem.Cell Biol. 42: 1472-1481. PM:20478393.
Baum, P, Schmid, R, Ittrich, C, Rust, W, Fundel-Clemens, K, Siewert, S, Baur, M, Mara, L, Gruenbaum, L, Heckel, A, Eils, R, Kontermann, RE, Roth, GJ, Gantner, F, Schnapp, A, Park, JE, Weith, A, Quast, K, and Mennerich, D. 2010. Phenocopy--a strategy to qualify chemical compounds during hit-to-lead and/or lead optimization. PLOS one. 5: e14272 PM:21170314.
Schneider, B, Munkel, S, Krippner-Heidenreich, A, Grunwald, I, Wels, WS, Wajant, H, Pfizenmaier, K, and Gerspach, J. 2010. Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins. Cell Death Dis. 1: e68 PM:21364672.
Smolders, I, Smets, I, Maier, O, vandeVen, M, Steels, P, and Ameloot, M. 2010. Simvastatin interferes with process outgrowth and branching of oligodendrocytes. J.Neurosci.Res. 88: 3361-3375. PM:20857509.
Wyzgol, A, Muller, N, Fick, A, Munkel, S, Grigoleit, GU, Pfizenmaier, K, and Wajant, H. 2009. Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand. J.Immunol. 183: 1851-1861. PM:19596991.
Peterburs, P, Heering, J, Link, G, Pfizenmaier, K, Olayioye, MA, and Hausser, A. 2009. Protein kinase D regulates cell migration by direct phosphorylation of the cofilin phosphatase slingshot 1 like. Cancer Res. 69: 5634-5638. PM:19567672.
Gerspach, J, Pfizenmaier, K, and Wajant, H. 2009. Improving TNF as a cancer therapeutic: tailor-made TNF fusion proteins with conserved antitumor activity and reduced systemic side effects. Biofactors. 35: 364-372. PM:19484741.
Fuchs, YF, Eisler, SA, Link, G, Schlicker, O, Bunt, G, Pfizenmaier, K, and Hausser, A. 2009. A Golgi PKD activity reporter reveals a crucial role of PKD in nocodazole-induced Golgi dispersal. Traffic. 10: 858-867. PM:19416469.
Messerschmidt, SK, Musyanovych, A, Altvater, M, Scheurich, P, Pfizenmaier, K, Landfester, K, and Kontermann, RE. 2009. Targeted lipid-coated nanoparticles: delivery of tumor necrosis factor-functionalized particles to tumor cells. J.Control Release. 137: 69-77. PM:19306900.
Czondor, K, Ellwanger, K, Fuchs, YF, Lutz, S, Gulyas, M, Mansuy, IM, Hausser, A, Pfizenmaier, K, and Schlett, K. 2009. Protein kinase D controls the integrity of Golgi apparatus and the maintenance of dendritic arborization in hippocampal neurons. Mol.Biol.Cell. 20: 2108-2120. PM:19211839.
Gerspach, J, Wajant, H, and Pfizenmaier, K. 2009. Death ligands designed to kill: development and application of targeted cancer therapeutics based on proapoptotic TNF family ligands. Results Probl.Cell Differ. 49: 241-273. PM:19142623.
Schlatter, R, Schmich, K, Avalos, V, I, Scheurich, P, Sauter, T, Borner, C, Ederer, M, Merfort, I, and Sawodny, O. 2009. ON/OFF and beyond--a boolean model of apoptosis. PLoS Comput.Biol. 5: e1000595 PM:20011108.
Ranzinger, J, Krippner-Heidenreich, A, Haraszti, T, Bock, E, Tepperink, J, Spatz, JP, and Scheurich, P. 2009. Nanoscale arrangement of apoptotic ligands reveals a demand for a minimal lateral distance for efficient death receptor activation. Nano.Lett. 9: 4240-4245. PM:19772290.
Wicovsky, A, Henkler, F, Salzmann, S, Scheurich, P, Kneitz, C, and Wajant, H. 2009. Tumor necrosis factor receptor-associated factor-1 enhances proinflammatory TNF receptor-2 signaling and modifies TNFR1-TNFR2 cooperation. Oncogene. 28: 1769-1781. PM:19287455.
Stork, R, Campigna, E, Robert, B, Muller, D, and Kontermann, RE. 2009. Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives. J.Biol.Chem. 284: 25612-25619. PM:19628871.
Kontermann, RE. 2009. Strategies to extend plasma half-lives of recombinant antibodies. BioDrugs. 23: 93-109. PM:19489651.
Beuttler, J, Rothdiener, M, Muller, D, Frejd, FY, and Kontermann, RE. 2009. Targeting of epidermal growth factor receptor (EGFR)-expressing tumor cells with sterically stabilized affibody liposomes (SAL). Bioconjug.Chem. 20: 1201-1208. PM:19435362.
Ahmadvand, D, Rasaee, MJ, Rahbarizadeh, F, Kontermann, RE, and Sheikholislami, F. 2009. Cell selection and characterization of a novel human endothelial cell specific nanobody. Mol.Immunol. 46: 1814-1823. PM:19249099.
Witt, J, Barisic, S, Schumann, E, Allgower, F, Sawodny, O, Sauter, T, and Kulms, D. 2009. Mechanism of PP2A-mediated IKK beta dephosphorylation: a systems biological approach. BMC.Syst.Biol. 3: 71 PM:19607706.
Sinnberg, T, Lasithiotakis, K, Niessner, H, Schittek, B, Flaherty, KT, Kulms, D, Maczey, E, Campos, M, Gogel, J, Garbe, C, and Meier, F. 2009. Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. J.Invest Dermatol. 129: 1500-1515. PM:19078992.
Thayaparasingham, B, Kunz, A, Peters, N, and Kulms, D. 2009. Sensitization of melanoma cells to TRAIL by UVB-induced and NF-kappaB-mediated downregulation of xIAP. Oncogene. 28: 345-362. PM:18978816.
Florin, L, Pegel, A, Becker, E, Hausser, A, Olayioye, MA, and Kaufmann, H. 2009. Heterologous expression of the lipid transfer protein CERT increases therapeutic protein productivity of mammalian cells. J.Biotechnol. 141: 84-90. PM:19428735.
Cowell, CF, Doppler, H, Yan, IK, Hausser, A, Umezawa, Y, and Storz, P. 2009. Mitochondrial diacylglycerol initiates protein-kinase D1-mediated ROS signaling. J.Cell Sci. 122: 919-928. PM:19258390.
Scholz, RP, Regner, J, Theil, A, Erlmann, P, Holeiter, G, Jahne, R, Schmid, S, Hausser, A, and Olayioye, MA. 2009. DLC1 interacts with 14-3-3 proteins to inhibit RhoGAP activity and block nucleocytoplasmic shuttling. J.Cell Sci. 122: 92-102. PM:19066281.
Erlmann, P, Schmid, S, Horenkamp, FA, Geyer, M, Pomorski, TG, and Olayioye, MA. 2009. DLC1 activation requires lipid interaction through a polybasic region preceding the RhoGAP domain. Mol.Biol.Cell. 20: 4400-4411. PM:19710422.
Heering, J, Erlmann, P, and Olayioye, MA. 2009. Simultaneous loss of the DLC1 and PTEN tumor suppressors enhances breast cancer cell migration. Exp.Cell Res. 315: 2505-2514. PM:19482022.
Breindl C, Waldherr, S, Hausser, A, and Allgower, F. 2009. Modeling cofilin mediated regulation of cell migration as a biochemical two-input switch. Proc.of the 3rd Foundations of Systems Biology in Engineering (FOSBE). Denver, Colorado, August 2009: 60-63.
Kontermann, R, Scheurich, P, and Pfizenmaier, K. 2009. Antagonists of TNF action: Clinical experiences and new developments. Expert Opin.Drug Discov. 4: 279-292.
Peterburs, P, Heering, J, Link, G, Pfizenmaier, K, Olayioye, MA, and Hausser, A. 2009. Protein kinase D regulates cell migration by direct phosphorylation of the cofilin phosphatase slingshot 1 like. Cancer Res. 69: 5634-5638. PM:19567672.
Gerspach, J, Pfizenmaier, K, and Wajant, H. 2009. Improving TNF as a cancer therapeutic: tailor-made TNF fusion proteins with conserved antitumor activity and reduced systemic side effects. Biofactors. 35: 364-372. PM:19484741.
Fuchs, YF, Eisler, SA, Link, G, Schlicker, O, Bunt, G, Pfizenmaier, K, and Hausser, A. 2009. A Golgi PKD activity reporter reveals a crucial role of PKD in nocodazole-induced Golgi dispersal. Traffic. 10: 858-867. PM:19416469.
Messerschmidt, SK, Musyanovych, A, Altvater, M, Scheurich, P, Pfizenmaier, K, Landfester, K, and Kontermann, RE. 2009. Targeted lipid-coated nanoparticles: delivery of tumor necrosis factor-functionalized particles to tumor cells. J.Control Release. 137: 69-77. PM:19306900.
Czondor, K, Ellwanger, K, Fuchs, YF, Lutz, S, Gulyas, M, Mansuy, IM, Hausser, A, Pfizenmaier, K, and Schlett, K. 2009. Protein kinase D controls the integrity of Golgi apparatus and the maintenance of dendritic arborization in hippocampal neurons. Mol.Biol.Cell. 20: 2108-2120. PM:19211839.
Gerspach, J, Wajant, H, and Pfizenmaier, K. 2009. Death ligands designed to kill: development and application of targeted cancer therapeutics based on proapoptotic TNF family ligands. Results Probl.Cell Differ. 49: 241-273. PM:19142623.
Schlatter, R, Schmich, K, Avalos, V, I, Scheurich, P, Sauter, T, Borner, C, Ederer, M, Merfort, I, and Sawodny, O. 2009. ON/OFF and beyond--a boolean model of apoptosis. PLoS Comput.Biol. 5: e1000595 PM:20011108.
Ranzinger, J, Krippner-Heidenreich, A, Haraszti, T, Bock, E, Tepperink, J, Spatz, JP, and Scheurich, P. 2009. Nanoscale arrangement of apoptotic ligands reveals a demand for a minimal lateral distance for efficient death receptor activation. Nano.Lett. 9: 4240-4245. PM:19772290.
Wicovsky, A, Henkler, F, Salzmann, S, Scheurich, P, Kneitz, C, and Wajant, H. 2009. Tumor necrosis factor receptor-associated factor-1 enhances proinflammatory TNF receptor-2 signaling and modifies TNFR1-TNFR2 cooperation. Oncogene. 28: 1769-1781. PM:19287455.
Stork, R, Campigna, E, Robert, B, Muller, D, and Kontermann, RE. 2009. Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives. J.Biol.Chem. 284: 25612-25619. PM:19628871.
Kontermann, RE. 2009. Strategies to extend plasma half-lives of recombinant antibodies. BioDrugs. 23: 93-109. PM:19489651.
Beuttler, J, Rothdiener, M, Muller, D, Frejd, FY, and Kontermann, RE. 2009. Targeting of epidermal growth factor receptor (EGFR)-expressing tumor cells with sterically stabilized affibody liposomes (SAL). Bioconjug.Chem. 20: 1201-1208. PM:19435362.
Ahmadvand, D, Rasaee, MJ, Rahbarizadeh, F, Kontermann, RE, and Sheikholislami, F. 2009. Cell selection and characterization of a novel human endothelial cell specific nanobody. Mol.Immunol. 46: 1814-1823. PM:19249099.
Witt, J, Barisic, S, Schumann, E, Allgower, F, Sawodny, O, Sauter, T, and Kulms, D. 2009. Mechanism of PP2A-mediated IKK beta dephosphorylation: a systems biological approach. BMC.Syst.Biol. 3: 71 PM:19607706.
Sinnberg, T, Lasithiotakis, K, Niessner, H, Schittek, B, Flaherty, KT, Kulms, D, Maczey, E, Campos, M, Gogel, J, Garbe, C, and Meier, F. 2009. Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. J.Invest Dermatol. 129: 1500-1515. PM:19078992.
Thayaparasingham, B, Kunz, A, Peters, N, and Kulms, D. 2009. Sensitization of melanoma cells to TRAIL by UVB-induced and NF-kappaB-mediated downregulation of xIAP. Oncogene. 28: 345-362. PM:18978816.
Florin, L, Pegel, A, Becker, E, Hausser, A, Olayioye, MA, and Kaufmann, H. 2009. Heterologous expression of the lipid transfer protein CERT increases therapeutic protein productivity of mammalian cells. J.Biotechnol. 141: 84-90. PM:19428735.
Cowell, CF, Doppler, H, Yan, IK, Hausser, A, Umezawa, Y, and Storz, P. 2009. Mitochondrial diacylglycerol initiates protein-kinase D1-mediated ROS signaling. J.Cell Sci. 122: 919-928. PM:19258390.
Scholz, RP, Regner, J, Theil, A, Erlmann, P, Holeiter, G, Jahne, R, Schmid, S, Hausser, A, and Olayioye, MA. 2009. DLC1 interacts with 14-3-3 proteins to inhibit RhoGAP activity and block nucleocytoplasmic shuttling. J.Cell Sci. 122: 92-102. PM:19066281.
Erlmann, P, Schmid, S, Horenkamp, FA, Geyer, M, Pomorski, TG, and Olayioye, MA. 2009. DLC1 activation requires lipid interaction through a polybasic region preceding the RhoGAP domain. Mol.Biol.Cell. 20: 4400-4411. PM:19710422.
Heering, J, Erlmann, P, and Olayioye, MA. 2009. Simultaneous loss of the DLC1 and PTEN tumor suppressors enhances breast cancer cell migration. Exp.Cell Res. 315: 2505-2514. PM:19482022.
Breindl C, Waldherr, S, Hausser, A, and Allgower, F. 2009. Modeling cofilin mediated regulation of cell migration as a biochemical two-input switch. Proc.of the 3rd Foundations of Systems Biology in Engineering (FOSBE). Denver, Colorado, August 2009: 60-63.
Kontermann, R, Scheurich, P, and Pfizenmaier, K. 2009. Antagonists of TNF action: Clinical experiences and new developments. Expert Opin.Drug Discov. 4: 279-292.
Krippner-Heidenreich, A, Grunwald, I, Zimmermann, G, Kuhnle, M, Gerspach, J, Sterns, T, Shnyder, SD, Gill, JH, Mannel, DN, Pfizenmaier, K, and Scheurich, P. 2008. Single-chain TNF, a TNF derivative with enhanced stability and antitumoral activity. J.Immunol. 180: 8176-8183. PM:18523283.
Becker, E, Florin, L, Pfizenmaier, K, and Kaufmann, H. 2008. An XBP-1 dependent bottle-neck in production of IgG subtype antibodies in chemically defined serum-free Chinese hamster ovary (CHO) fed-batch processes. J.Biotechnol. 135: 217-223. PM:18448183.
Ellwanger, K, Pfizenmaier, K, Lutz, S, and Hausser, A. 2008. Expression patterns of protein kinase D 3 during mouse development. BMC.Dev.Biol. 8: 47 PM:18439271.
Muller, N, Wyzgol, A, Munkel, S, Pfizenmaier, K, and Wajant, H. 2008. Activity of soluble OX40 ligand is enhanced by oligomerization and cell surface immobilization. FEBS J. 275: 2296-2304. PM:18397322.
Ha, CH, Wang, W, Jhun, BS, Wong, C, Hausser, A, Pfizenmaier, K, McKinsey, TA, Olson, EN, and Jin, ZG. 2008. Protein kinase D-dependent phosphorylation and nuclear export of histone deacetylase 5 mediates vascular endothelial growth factor-induced gene expression and angiogenesis. J.Biol.Chem. 283: 14590-14599. PM:18332134.
Kontermann, RE, Munkel, S, Neumeyer, J, Muller, D, Branschadel, M, Scheurich, P, and Pfizenmaier, K. 2008. A humanized tumor necrosis factor receptor 1 (TNFR1)-specific antagonistic antibody for selective inhibition of tumor necrosis factor (TNF) action. J.Immunother. 31: 225-234. PM:18317365.
Johnson, TS, Mahnke, K, Storn, V, Schonfeld, K, Ring, S, Nettelbeck, DM, Haisma, HJ, Le Gall, F, Kontermann, RE, and Enk, AH. 2008. Inhibition of melanoma growth by targeting of antigen to dendritic cells via an anti-DEC-205 single-chain fragment variable molecule. Clin.Cancer Res. 14: 8169-8177. PM:19088032.
Muller, D, Trunk, G, Sichelstiel, A, Zettlitz, KA, Quintanilla, M, and Kontermann, RE. 2008. Murine endoglin-specific single-chain Fv fragments for the analysis of vascular targeting strategies in mice. J.Immunol.Methods. 339: 90-98. PM:18790696.
Muller, D, Frey, K, and Kontermann, RE. 2008. A novel antibody-4-1BBL fusion protein for targeted costimulation in cancer immunotherapy. J.Immunother. 31: 714-722. PM:18779748.
Stork, R, Zettlitz, KA, Muller, D, Rether, M, Hanisch, FG, and Kontermann, RE. 2008. N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies. J.Biol.Chem. 283: 7804-7812. PM:18211902.
Messerschmidt, SK, Kolbe, A, Muller, D, Knoll, M, Pleiss, J, and Kontermann, RE. 2008. Novel single-chain Fv' formats for the generation of immunoliposomes by site-directed coupling. Bioconjug.Chem. 19: 362-369. PM:17988079.
Barisic, S, Strozyk, E, Peters, N, Walczak, H, and Kulms, D. 2008. Identification of PP2A as a crucial regulator of the NF-kappaB feedback loop: its inhibition by UVB turns NF-kappaB into a pro-apoptotic factor. Cell Death.Differ. 15: 1681-1690. PM:18583989.
Lasithiotakis, KG, Sinnberg, TW, Schittek, B, Flaherty, KT, Kulms, D, Maczey, E, Garbe, C, and Meier, FE. 2008. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J.Invest Dermatol. 128: 2013-2023. PM:18323781.
Singer-Kruger, B, Lasic, M, Burger, AM, Hausser, A, Pipkorn, R, and Wang, Y. 2008. Yeast and human Ysl2p/hMon2 interact with Gga adaptors and mediate their subcellular distribution. EMBO J. 27: 1423-1435. PM:18418388.
Holeiter, G, Heering, J, Erlmann, P, Schmid, S, Jahne, R, and Olayioye, MA. 2008. Deleted in liver cancer 1 controls cell migration through a Dia1-dependent signaling pathway. Cancer Res. 68: 8743-8751. PM:18974116.
Muller, E and Faude, A. 2008. Investigation of salt properties with electro-acoustic measurements and their effect on dynamic binding capacity in hydrophobic interaction chromatography. J.Chromatogr.A. 1177: 215-225. PM:18037423.
Becker, E, Florin, L, Pfizenmaier, K, and Kaufmann, H. 2008. An XBP-1 dependent bottle-neck in production of IgG subtype antibodies in chemically defined serum-free Chinese hamster ovary (CHO) fed-batch processes. J.Biotechnol. 135: 217-223. PM:18448183.
Ellwanger, K, Pfizenmaier, K, Lutz, S, and Hausser, A. 2008. Expression patterns of protein kinase D 3 during mouse development. BMC.Dev.Biol. 8: 47 PM:18439271.
Muller, N, Wyzgol, A, Munkel, S, Pfizenmaier, K, and Wajant, H. 2008. Activity of soluble OX40 ligand is enhanced by oligomerization and cell surface immobilization. FEBS J. 275: 2296-2304. PM:18397322.
Ha, CH, Wang, W, Jhun, BS, Wong, C, Hausser, A, Pfizenmaier, K, McKinsey, TA, Olson, EN, and Jin, ZG. 2008. Protein kinase D-dependent phosphorylation and nuclear export of histone deacetylase 5 mediates vascular endothelial growth factor-induced gene expression and angiogenesis. J.Biol.Chem. 283: 14590-14599. PM:18332134.
Kontermann, RE, Munkel, S, Neumeyer, J, Muller, D, Branschadel, M, Scheurich, P, and Pfizenmaier, K. 2008. A humanized tumor necrosis factor receptor 1 (TNFR1)-specific antagonistic antibody for selective inhibition of tumor necrosis factor (TNF) action. J.Immunother. 31: 225-234. PM:18317365.
Johnson, TS, Mahnke, K, Storn, V, Schonfeld, K, Ring, S, Nettelbeck, DM, Haisma, HJ, Le Gall, F, Kontermann, RE, and Enk, AH. 2008. Inhibition of melanoma growth by targeting of antigen to dendritic cells via an anti-DEC-205 single-chain fragment variable molecule. Clin.Cancer Res. 14: 8169-8177. PM:19088032.
Muller, D, Trunk, G, Sichelstiel, A, Zettlitz, KA, Quintanilla, M, and Kontermann, RE. 2008. Murine endoglin-specific single-chain Fv fragments for the analysis of vascular targeting strategies in mice. J.Immunol.Methods. 339: 90-98. PM:18790696.
Muller, D, Frey, K, and Kontermann, RE. 2008. A novel antibody-4-1BBL fusion protein for targeted costimulation in cancer immunotherapy. J.Immunother. 31: 714-722. PM:18779748.
Stork, R, Zettlitz, KA, Muller, D, Rether, M, Hanisch, FG, and Kontermann, RE. 2008. N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies. J.Biol.Chem. 283: 7804-7812. PM:18211902.
Messerschmidt, SK, Kolbe, A, Muller, D, Knoll, M, Pleiss, J, and Kontermann, RE. 2008. Novel single-chain Fv' formats for the generation of immunoliposomes by site-directed coupling. Bioconjug.Chem. 19: 362-369. PM:17988079.
Barisic, S, Strozyk, E, Peters, N, Walczak, H, and Kulms, D. 2008. Identification of PP2A as a crucial regulator of the NF-kappaB feedback loop: its inhibition by UVB turns NF-kappaB into a pro-apoptotic factor. Cell Death.Differ. 15: 1681-1690. PM:18583989.
Lasithiotakis, KG, Sinnberg, TW, Schittek, B, Flaherty, KT, Kulms, D, Maczey, E, Garbe, C, and Meier, FE. 2008. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J.Invest Dermatol. 128: 2013-2023. PM:18323781.
Singer-Kruger, B, Lasic, M, Burger, AM, Hausser, A, Pipkorn, R, and Wang, Y. 2008. Yeast and human Ysl2p/hMon2 interact with Gga adaptors and mediate their subcellular distribution. EMBO J. 27: 1423-1435. PM:18418388.
Holeiter, G, Heering, J, Erlmann, P, Schmid, S, Jahne, R, and Olayioye, MA. 2008. Deleted in liver cancer 1 controls cell migration through a Dia1-dependent signaling pathway. Cancer Res. 68: 8743-8751. PM:18974116.
Muller, E and Faude, A. 2008. Investigation of salt properties with electro-acoustic measurements and their effect on dynamic binding capacity in hydrophobic interaction chromatography. J.Chromatogr.A. 1177: 215-225. PM:18037423.
Xu, X, Ha, CH, Wong, C, Wang, W, Hausser, A, Pfizenmaier, K, Olson, EN, McKinsey, TA, and Jin, ZG. 2007. Angiotensin II stimulates protein kinase D-dependent histone deacetylase 5 phosphorylation and nuclear export leading to vascular smooth muscle cell hypertrophy. Arterioscler.Thromb.Vasc.Biol. 27: 2355-2362. PM:17823368.
Eiseler, T, Schmid, MA, Topbas, F, Pfizenmaier, K, and Hausser, A. 2007. PKD is recruited to sites of actin remodelling at the leading edge and negatively regulates cell migration. FEBS Lett. 581: 4279-4287. PM:17707375.
Berg, D, Lehne, M, Muller, N, Siegmund, D, Munkel, S, Sebald, W, Pfizenmaier, K, and Wajant, H. 2007. Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L. Cell Death.Differ. 14: 2021-2034. PM:17703232.
Fugmann, T, Hausser, A, Schoffler, P, Schmid, S, Pfizenmaier, K, and Olayioye, MA. 2007. Regulation of secretory transport by protein kinase D-mediated phosphorylation of the ceramide transfer protein. J.Cell Biol. 178: 15-22. PM:17591919.
Watermann, I, Gerspach, J, Lehne, M, Seufert, J, Schneider, B, Pfizenmaier, K, and Wajant, H. 2007. Activation of CD95L fusion protein prodrugs by tumor-associated proteases. Cell Death.Differ. 14: 765-774. PM:17053806.
Eissing, T, Waldherr, S, Allgower, F, Scheurich, P, and Bullinger, E. 2007. Steady state and (bi-) stability evaluation of simple protease signalling networks. Biosystems. 90: 591-601. PM:17314003.
Eissing, T, Waldherr, S, Allgower, F, Scheurich, P, and Bullinger, E. 2007. Response to bistability in apoptosis: roles of bax, bcl-2, and mitochondrial permeability transition pores. Biophys.J. 92: 3332-3334. PM:17277182.
Stork, R, Muller, D, and Kontermann, RE. 2007. A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G. Protein Eng Des Sel. 20: 569-576. PM:17982179.
Muller, D and Kontermann, RE. 2007. Recombinant bispecific antibodies for cellular cancer immunotherapy. Curr.Opin.Mol.Ther. 9: 319-326. PM:17694444.
Baum, P, Muller, D, Ruger, R, and Kontermann, RE. 2007. Single-chain Fv immunoliposomes for the targeting of fibroblast activation protein-expressing tumor stromal cells. J.Drug Target. 15: 399-406. PM:17613658.
Muller, D, Karle, A, Meissburger, B, Hofig, I, Stork, R, and Kontermann, RE. 2007. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J.Biol.Chem. 282: 12650-12660. PM:17347147.
Hesse, A, Kosmides, D, Kontermann, RE, and Nettelbeck, DM. 2007. Tropism modification of adenovirus vectors by peptide ligand insertion into various positions of the adenovirus serotype 41 short-fiber knob domain. J.Virol. 81: 2688-2699. PM:17192304.
Meier, F, Busch, S, Lasithiotakis, K, Kulms, D, Garbe, C, Maczey, E, Herlyn, M, and Schittek, B. 2007. Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. Br.J.Dermatol. 156: 1204-1213. PM:17388918.
Maier, D, Nagel, AC, Gloc, H, Hausser, A, Kugler, SJ, Wech, I, and Preiss, A. 2007. Protein kinase D regulates several aspects of development in Drosophila melanogaster. BMC.Dev.Biol. 7: 74 PM:17592635.
Olayioye, MA, Buchholz, M, Schmid, S, Schoffler, P, Hoffmann, P, and Pomorski, T. 2007. Phosphorylation of StarD10 on serine 284 by casein kinase II modulates its lipid transfer activity. J.Biol.Chem. 282: 22492-22498. PM:17561512.
Faude, A, Zacher, D, Muller, E, and Bottinger, H. 2007. Fast determination of conditions for maximum dynamic capacity in cation-exchange chromatography of human monoclonal antibodies. J.Chromatogr.A. 1161: 29-35. PM:17442329.
Witt, J, Husser, S, Kulms, D, Barisic, S, Sawodny, O, and Sauter, T. 2007. Modeling of IL-1 induced Nf-kappaB signaling and analysis of additional UVB influence. SICE Annu.Conf. 1353-1358.
Eiseler, T, Schmid, MA, Topbas, F, Pfizenmaier, K, and Hausser, A. 2007. PKD is recruited to sites of actin remodelling at the leading edge and negatively regulates cell migration. FEBS Lett. 581: 4279-4287. PM:17707375.
Berg, D, Lehne, M, Muller, N, Siegmund, D, Munkel, S, Sebald, W, Pfizenmaier, K, and Wajant, H. 2007. Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L. Cell Death.Differ. 14: 2021-2034. PM:17703232.
Fugmann, T, Hausser, A, Schoffler, P, Schmid, S, Pfizenmaier, K, and Olayioye, MA. 2007. Regulation of secretory transport by protein kinase D-mediated phosphorylation of the ceramide transfer protein. J.Cell Biol. 178: 15-22. PM:17591919.
Watermann, I, Gerspach, J, Lehne, M, Seufert, J, Schneider, B, Pfizenmaier, K, and Wajant, H. 2007. Activation of CD95L fusion protein prodrugs by tumor-associated proteases. Cell Death.Differ. 14: 765-774. PM:17053806.
Eissing, T, Waldherr, S, Allgower, F, Scheurich, P, and Bullinger, E. 2007. Steady state and (bi-) stability evaluation of simple protease signalling networks. Biosystems. 90: 591-601. PM:17314003.
Eissing, T, Waldherr, S, Allgower, F, Scheurich, P, and Bullinger, E. 2007. Response to bistability in apoptosis: roles of bax, bcl-2, and mitochondrial permeability transition pores. Biophys.J. 92: 3332-3334. PM:17277182.
Stork, R, Muller, D, and Kontermann, RE. 2007. A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G. Protein Eng Des Sel. 20: 569-576. PM:17982179.
Muller, D and Kontermann, RE. 2007. Recombinant bispecific antibodies for cellular cancer immunotherapy. Curr.Opin.Mol.Ther. 9: 319-326. PM:17694444.
Baum, P, Muller, D, Ruger, R, and Kontermann, RE. 2007. Single-chain Fv immunoliposomes for the targeting of fibroblast activation protein-expressing tumor stromal cells. J.Drug Target. 15: 399-406. PM:17613658.
Muller, D, Karle, A, Meissburger, B, Hofig, I, Stork, R, and Kontermann, RE. 2007. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J.Biol.Chem. 282: 12650-12660. PM:17347147.
Hesse, A, Kosmides, D, Kontermann, RE, and Nettelbeck, DM. 2007. Tropism modification of adenovirus vectors by peptide ligand insertion into various positions of the adenovirus serotype 41 short-fiber knob domain. J.Virol. 81: 2688-2699. PM:17192304.
Meier, F, Busch, S, Lasithiotakis, K, Kulms, D, Garbe, C, Maczey, E, Herlyn, M, and Schittek, B. 2007. Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. Br.J.Dermatol. 156: 1204-1213. PM:17388918.
Maier, D, Nagel, AC, Gloc, H, Hausser, A, Kugler, SJ, Wech, I, and Preiss, A. 2007. Protein kinase D regulates several aspects of development in Drosophila melanogaster. BMC.Dev.Biol. 7: 74 PM:17592635.
Olayioye, MA, Buchholz, M, Schmid, S, Schoffler, P, Hoffmann, P, and Pomorski, T. 2007. Phosphorylation of StarD10 on serine 284 by casein kinase II modulates its lipid transfer activity. J.Biol.Chem. 282: 22492-22498. PM:17561512.
Faude, A, Zacher, D, Muller, E, and Bottinger, H. 2007. Fast determination of conditions for maximum dynamic capacity in cation-exchange chromatography of human monoclonal antibodies. J.Chromatogr.A. 1161: 29-35. PM:17442329.
Witt, J, Husser, S, Kulms, D, Barisic, S, Sawodny, O, and Sauter, T. 2007. Modeling of IL-1 induced Nf-kappaB signaling and analysis of additional UVB influence. SICE Annu.Conf. 1353-1358.
Assohou-Luty, C, Gerspach, J, Siegmund, D, Muller, N, Huard, B, Tiegs, G, Pfizenmaier, K, and Wajant, H. 2006. A CD40-CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95. J.Mol.Med. 84: 785-797. PM:16924474.
Hausser, A, Link, G, Hoene, M, Russo, C, Selchow, O, and Pfizenmaier, K. 2006. Phospho-specific binding of 14-3-3 proteins to phosphatidylinositol 4-kinase III beta protects from dephosphorylation and stabilizes lipid kinase activity. J.Cell Sci. 119: 3613-3621. PM:16912074.
Beisner, J, Buck, MB, Fritz, P, Dippon, J, Schwab, M, Brauch, H, Zugmaier, G, Pfizenmaier, K, and Knabbe, C. 2006. A novel functional polymorphism in the transforming growth factor-beta2 gene promoter and tumor progression in breast cancer. Cancer Res. 66: 7554-7561. PM:16885354.
Maier, D, Hausser, A, Nagel, AC, Link, G, Kugler, SJ, Wech, I, Pfizenmaier, K, and Preiss, A. 2006. Drosophila protein kinase D is broadly expressed and a fraction localizes to the Golgi compartment. Gene Expr.Patterns. 6: 849-856. PM:16750940.
Gerspach, J, Nemeth, J, Munkel, S, Wajant, H, and Pfizenmaier, K. 2006. Target-selective activation of a TNF prodrug by urokinase-type plasminogen activator (uPA) mediated proteolytic processing at the cell surface. Cancer Immunol.Immunother. 55: 1590-1600. PM:16636812.
Gerspach, J, Muller, D, Munkel, S, Selchow, O, Nemeth, J, Noack, M, Petrul, H, Menrad, A, Wajant, H, and Pfizenmaier, K. 2006. Restoration of membrane TNF-like activity by cell surface targeting and matrix metalloproteinase-mediated processing of a TNF prodrug. Cell Death.Differ. 13: 273-284. PM:16052236.
Ruger, R, Muller, D, Fahr, A, and Kontermann, RE. 2006. In vitro characterization of binding and stability of single-chain Fv Ni-NTA-liposomes. J.Drug Target. 14: 576-582. PM:17050123.
Kontermann, RE. 2006. Immunoliposomes for cancer therapy. Curr.Opin.Mol.Ther. 8: 39-45. PM:16506524.
Kulms, D and Schwarz, T. 2006. NF-kappaB and cytokines. Vitam.Horm. 74: 283-300. PM:17027519.
Strozyk, E, Poppelmann, B, Schwarz, T, and Kulms, D. 2006. Differential effects of NF-kappaB on apoptosis induced by DNA-damaging agents: the type of DNA damage determines the final outcome. Oncogene. 25: 6239-6251. PM:16702954.
Hausser, A, Link, G, Hoene, M, Russo, C, Selchow, O, and Pfizenmaier, K. 2006. Phospho-specific binding of 14-3-3 proteins to phosphatidylinositol 4-kinase III beta protects from dephosphorylation and stabilizes lipid kinase activity. J.Cell Sci. 119: 3613-3621. PM:16912074.
Beisner, J, Buck, MB, Fritz, P, Dippon, J, Schwab, M, Brauch, H, Zugmaier, G, Pfizenmaier, K, and Knabbe, C. 2006. A novel functional polymorphism in the transforming growth factor-beta2 gene promoter and tumor progression in breast cancer. Cancer Res. 66: 7554-7561. PM:16885354.
Maier, D, Hausser, A, Nagel, AC, Link, G, Kugler, SJ, Wech, I, Pfizenmaier, K, and Preiss, A. 2006. Drosophila protein kinase D is broadly expressed and a fraction localizes to the Golgi compartment. Gene Expr.Patterns. 6: 849-856. PM:16750940.
Gerspach, J, Nemeth, J, Munkel, S, Wajant, H, and Pfizenmaier, K. 2006. Target-selective activation of a TNF prodrug by urokinase-type plasminogen activator (uPA) mediated proteolytic processing at the cell surface. Cancer Immunol.Immunother. 55: 1590-1600. PM:16636812.
Gerspach, J, Muller, D, Munkel, S, Selchow, O, Nemeth, J, Noack, M, Petrul, H, Menrad, A, Wajant, H, and Pfizenmaier, K. 2006. Restoration of membrane TNF-like activity by cell surface targeting and matrix metalloproteinase-mediated processing of a TNF prodrug. Cell Death.Differ. 13: 273-284. PM:16052236.
Ruger, R, Muller, D, Fahr, A, and Kontermann, RE. 2006. In vitro characterization of binding and stability of single-chain Fv Ni-NTA-liposomes. J.Drug Target. 14: 576-582. PM:17050123.
Kontermann, RE. 2006. Immunoliposomes for cancer therapy. Curr.Opin.Mol.Ther. 8: 39-45. PM:16506524.
Kulms, D and Schwarz, T. 2006. NF-kappaB and cytokines. Vitam.Horm. 74: 283-300. PM:17027519.
Strozyk, E, Poppelmann, B, Schwarz, T, and Kulms, D. 2006. Differential effects of NF-kappaB on apoptosis induced by DNA-damaging agents: the type of DNA damage determines the final outcome. Oncogene. 25: 6239-6251. PM:16702954.
Bryde, S, Grunwald, I, Hammer, A, Krippner-Heidenreich, A, Schiestel, T, Brunner, H, Tovar, GE, Pfizenmaier, K, and Scheurich, P. 2005. Tumor necrosis factor (TNF)-functionalized nanostructured particles for the stimulation of membrane TNF-specific cell responses. Bioconjug.Chem. 16: 1459-1467. PM:16287242.
Hausser, A, Storz, P, Martens, S, Link, G, Toker, A, and Pfizenmaier, K. 2005. Protein kinase D regulates vesicular transport by phosphorylating and activating phosphatidylinositol-4 kinase IIIbeta at the Golgi complex. Nat.Cell Biol. 7: 880-886. PM:16100512.
Henkler, F, Behrle, E, Dennehy, KM, Wicovsky, A, Peters, N, Warnke, C, Pfizenmaier, K, and Wajant, H. 2005. The extracellular domains of FasL and Fas are sufficient for the formation of supramolecular FasL-Fas clusters of high stability. J.Cell Biol. 168: 1087-1098. PM:15795317.
Wajant, H, Gerspach, J, and Pfizenmaier, K. 2005. Tumor therapeutics by design: targeting and activation of death receptors. Cytokine Growth Factor Rev. 16: 55-76. PM:15733832.
Fotin-Mleczek, M, Welte, S, Mader, O, Duchardt, F, Fischer, R, Hufnagel, H, Scheurich, P, and Brock, R. 2005. Cationic cell-penetrating peptides interfere with TNF signalling by induction of TNF receptor internalization. J.Cell Sci. 118: 3339-3351. PM:16079278.
Till, A, Rosenstiel, P, Krippner-Heidenreich, A, Mascheretti-Croucher, S, Croucher, PJ, Schafer, H, Scheurich, P, Seegert, D, and Schreiber, S. 2005. The Met-196 -> Arg variation of human tumor necrosis factor receptor 2 (TNFR2) affects TNF-alpha-induced apoptosis by impaired NF-kappaB signaling and target gene expression. J.Biol.Chem. 280: 5994-6004. PM:15572357.
Ruger, R, Muller, D, Fahr, A, and Kontermann, RE. 2005. Generation of immunoliposomes using recombinant single-chain Fv fragments bound to Ni-NTA-liposomes. J.Drug Target. 13: 399-406. PM:16308208.
Smith, J, Kontermann, RE, Embleton, J, and Kumar, S. 2005. Antibody phage display technologies with special reference to angiogenesis. FASEB J. 19: 331-341. PM:15746176. Kontermann, RE. 2005. Recombinant bispecific antibodies for cancer therapy. Acta Pharmacol.Sin. 26: 1-9. PM:15659107.
Poppelmann, B, Klimmek, K, Strozyk, E, Voss, R, Schwarz, T, and Kulms, D. 2005. NF{kappa}B-dependent down-regulation of tumor necrosis factor receptor-associated proteins contributes to interleukin-1-mediated enhancement of ultraviolet B-induced apoptosis. J.Biol.Chem. 280: 15635-15643. PM:15723831.
Hausser, A, Storz, P, Martens, S, Link, G, Toker, A, and Pfizenmaier, K. 2005. Protein kinase D regulates vesicular transport by phosphorylating and activating phosphatidylinositol-4 kinase IIIbeta at the Golgi complex. Nat.Cell Biol. 7: 880-886. PM:16100512.
Henkler, F, Behrle, E, Dennehy, KM, Wicovsky, A, Peters, N, Warnke, C, Pfizenmaier, K, and Wajant, H. 2005. The extracellular domains of FasL and Fas are sufficient for the formation of supramolecular FasL-Fas clusters of high stability. J.Cell Biol. 168: 1087-1098. PM:15795317.
Wajant, H, Gerspach, J, and Pfizenmaier, K. 2005. Tumor therapeutics by design: targeting and activation of death receptors. Cytokine Growth Factor Rev. 16: 55-76. PM:15733832.
Fotin-Mleczek, M, Welte, S, Mader, O, Duchardt, F, Fischer, R, Hufnagel, H, Scheurich, P, and Brock, R. 2005. Cationic cell-penetrating peptides interfere with TNF signalling by induction of TNF receptor internalization. J.Cell Sci. 118: 3339-3351. PM:16079278.
Till, A, Rosenstiel, P, Krippner-Heidenreich, A, Mascheretti-Croucher, S, Croucher, PJ, Schafer, H, Scheurich, P, Seegert, D, and Schreiber, S. 2005. The Met-196 -> Arg variation of human tumor necrosis factor receptor 2 (TNFR2) affects TNF-alpha-induced apoptosis by impaired NF-kappaB signaling and target gene expression. J.Biol.Chem. 280: 5994-6004. PM:15572357.
Ruger, R, Muller, D, Fahr, A, and Kontermann, RE. 2005. Generation of immunoliposomes using recombinant single-chain Fv fragments bound to Ni-NTA-liposomes. J.Drug Target. 13: 399-406. PM:16308208.
Smith, J, Kontermann, RE, Embleton, J, and Kumar, S. 2005. Antibody phage display technologies with special reference to angiogenesis. FASEB J. 19: 331-341. PM:15746176. Kontermann, RE. 2005. Recombinant bispecific antibodies for cancer therapy. Acta Pharmacol.Sin. 26: 1-9. PM:15659107.
Poppelmann, B, Klimmek, K, Strozyk, E, Voss, R, Schwarz, T, and Kulms, D. 2005. NF{kappa}B-dependent down-regulation of tumor necrosis factor receptor-associated proteins contributes to interleukin-1-mediated enhancement of ultraviolet B-induced apoptosis. J.Biol.Chem. 280: 15635-15643. PM:15723831.